"It is our commitment to the continuous expansion in the Chinese market, echoing the country's move to reform its medical services," said
The investment, part of GE's $2 billion for the Chinese market through 2012, will be used to expand R&D and innovation capabilities for new technologies in healthcare, said Diana Tang, general manager of Clinic System Business, GE Healthcare China.
Worldwide, GE Healthcare is investing $1 billion each year in R&D, more than 6.7% of its revenue in 2009.
The $500 million will largely go to setting up six R&D and innovation centers in China in the next three years, the first three to be built in Chengdu in Sichuan province, Xi'an in Shaanxi province, and Shenyang in Liaoning province. The locations of the other three are under discussion, Tang said, adding that 1,000 engineers will be hired for the new centers.
The centers will be closely linked to GE's current R&D activities in Shanghai, Beijing, and Wuxi in Jiangsu province to better meet the needs of the local market, said Wu Tao, chairman of GE Medical Systems (China) Co Ltd.
"Research will be focused on developing medical facilities for cancer, stroke, and other age-related diseases," Wu said.
He said GE Healthcare will spend $8 million on enlarging its Wuxi R&D center this year. The project will be completed by the end of next year.
Construction of the R&D centers is intended to increase GE Healthcare's medical product sales in China from this year's estimated $1 billion to $3 billion within five years to advance its "in China, for China" strategy, launched in 2007, Tang said.
The strategy covers such fields as ultrasound, CT and monitoring systems, including its first B30 patient monitoring system, which was developed for China's market by adapting global technologies.
B30 monitors, launched last week, target the emerging healthcare market in China to help improve basic healthcare conditions for people here, said Xi Shui, general manager of Patient Care Solutions, GE Healthcare China.
There were 4.41 million clinic beds around China in 2009, a number expected to increase by 8 percent annually until 2015.
"The market has such big potential, it encourages us to invest more in developing new products for it," Xi said.
GE Healthcare now has 17 ICFC products launched in or in the pipeline for China, with a total investment of around $70 million, part of its global "Healthymagination" strategy, valued at $6 billion, Tang said.
At present, 85% of the products from the Wuxi factory are exported overseas, and only 15% sold to the domestic market, Xi said.
"But efforts will be made to balance that ratio in the next five years to reach a fifty-fifty rate," he said.
China is expected to require 120,000 patient monitors annually, valued at $200 million, but GE's market share is only at 15%, lagging far behind its 30 percent of the $3.2 billion sales in the global market, Wu said.
GE Healthcare has invested $30 million in China this year to develop new products and $10 million to develop personnel. – Source: ChinaDaily.com